RHB-102 (Bekinda®) (24 mg), an investigational drug, is in development in the UK for the management of chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV, respectively) in adults, with a Marketing Authorization Application (MAA) planned.
RHB-102 is a proprietary bimodal immediate and extended-release, once-daily oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist. RHB-102 is intended to provide patients with relief from nausea and vomiting symptoms for 24 hours with a single oral tablet.